文献速递细菌感染、耐药与抗菌药物新发突发、热带与寄生虫病

高耐药时代新抗生素的非劣效与优效试验设计:上市后适应性随机对照试验的倡导

Non-inferiority versus superiority trial design for new antibiotics in an era of high antimicrobial resistance: the case for post-marketing, adaptive randomised controlled trials.
PubMed 文献 · Lancet Infect Dis · 2019-08-23

抗菌素耐药是全球卫生安全重大威胁,多重耐药革兰阴性菌相关药物(头孢他啶-阿维巴坦、普拉佐米星、美罗培南-伐硼巴坦)基于非劣效试验获批,但缺乏针对多重耐药菌的直接疗效证据。文章以头孢他啶-阿维巴坦研发为例,提出基于适应性随机临床试验的新研究框架,旨在评估新抗生素在多重耐药菌感染等特殊患者群体中的疗效。

要点

  • 多重耐药革兰阴性菌对几乎所有现有抗生素耐药,新药审批依赖非劣效试验但缺乏直接疗效证据。
  • 非劣效与优效试验的选择及优化设计是新抗生素研发、注册和上市后实施的主要挑战。
  • 建议采用适应性随机临床试验框架,评估新抗生素在多重耐药菌感染等特殊人群中的疗效。

核心结论

  • 新抗生素基于非劣效试验获批,缺乏针对多重耐药革兰阴性菌的直接疗效证据,需采用上市后适应性随机对照试验评估特殊人群疗效。

研究设计与样本

  • 本文为综述/观点类文章,以头孢他啶-阿维巴坦研发过程为例,提出基于适应性随机临床试验的新研究框架。

主要发现

  • 头孢他啶-阿维巴坦、普拉佐米星和美罗培南-伐硼巴坦基于非劣效试验获批,但无直接证据证明其对多重耐药肠杆菌科、铜绿假单胞菌、嗜麦芽窄食单胞菌、洋葱伯克霍尔德菌和鲍曼不动杆菌的疗效。

临床怎么用

  • 临床应关注新抗生素在多重耐药菌感染等未纳入早期试验的特殊患者群体中的疗效评估,并建立合适的标准治疗方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Antimicrobial resistance is one of the most important threats to global health security. A range of Gram-negative bacteria associated with high morbidity and mortality are now resistant to almost all available antibiotics. In this context of urgency to develop novel drugs, new antibiotics for multidrug-resistant Gram-negative bacteria (namely, ceftazidime-avibactam, plazomicin, and meropenem-vaborbactam) have been approved by regulatory authorities based on non-inferiority trials that provided no direct evidence of their efficacy against multidrug-resistant bacteria such as Enterobacteriaceae spp, Pseudomonas aeruginosa, Stenotrophomonas maltophilia, Burkholderia cepacia, and Acinetobacter baumannii. The use of non-inferiority and superiority trials, and selection of appropriate and optimal study designs, remains a major challenge in the development, registration, and post-marketing implementation of new antibiotics. Using an example of the development process of ceftazidime-avibactam, we propose a strategy for a new research framework based on adaptive randomised clinical trials. The operational research strategy has the aim of assessing the efficacy of new antibiotics in special groups of patients, such as those infected with multidrug-resistant bacteria, who were not included in earlier phase studies, and for whom it is important to establish an appropriate standard of care.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Lanini S, Ioannidis JPA, Vairo F, et al. Non-inferiority versus superiority trial design for new antibiotics in an era of high antimicrobial resistance: the case for post-marketing, adaptive randomised controlled trials. Lancet Infect Dis. 2019. PMID: 31451421. doi:10.1016/S1473-3099(19)30284-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。